Accessibility Menu
Sight Sciences logo

Sight Sciences(NASDAQ) SGHT

Market Cap$286.20MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2021)-84%
5 Year-86%
1 Year+52%
1 Month-3%
$5.25
-0.29%
-0.01Today
After hours$5.26+$0.02 (+0.29%)
Sight Sciences last closing stock price
MetricPriceDate
Last closeUSD 5.262026-07-30
Sight Sciences stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+11.91%USD 4.702026-07-23
1 month-2.95%USD 5.422026-06-30
3 month+18.2%USD 4.452026-05-01
Year to date-33.67%USD 7.932025-12-31
1 year+52.46%USD 3.452025-07-30
3 year-40.23%USD 8.802023-07-31
5 year-85.77%USD 36.972021-07-30
Since inception-84.3%USD 33.502021-07-15

Sight Sciences Financials at a Glance

Market Cap

$286.20MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$79.55M

Net Income (TTM)

-$37.25M

EPS (TTM)

-$0.71

P/E Ratio

-7.46

Dividend

$0.00

Beta (Volatility)

1.87 (High)

Price

$5.25

Volume

95,733.867

Open

$5.26

Previous Close

$5.26

Daily Range

$5.10 - $5.31

52-Week Range

$3.11 - $9.24

Estimated Earnings Date

Aug 5, 2026

SGHT News

GettyImages-1273470469

Here's What Investors Need to Know About Sight Sciences Stock

Rachel WarrenJan 12, 2022
GettyImages-1279371084

Should Investors Consider Sight Sciences Stock?

Rachel WarrenJan 10, 2022

SGHT: Motley Fool Moneyball Superscore

51

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Sight Sciences

Sight Sciences makes tools to help doctors treat eye problems. These devices help people keep their vision through simple procedures. They focus on fixing eye pressure and dry eye disease.

Helping People Keep Seeing

  • Interventional Glaucoma: Surgical tools used to reduce eye pressure without permanent implants; accounted for 93.1% of revenue in the first quarter of 2026.
  • Interventional Dry Eye: Wearable eyelid devices and manual expression tools used to clear blocked oil glands; represented 6.9% of revenue in the first quarter of 2026.

Strategic Moves and Legal Wins

  • Won a $55.4 million final judgment in April 2026 in a patent infringement lawsuit against Alcon.
  • Secured a credit facility for up to $65 million from Hercules Capital in January 2024 to support operations.
  • Launched a targeted restructuring plan in the third quarter of 2025 to improve cost efficiency and reach profitability.
  • Expanded third-party manufacturing options with new capacity expected to be available in the second quarter of 2026.

Training a Specialized Sales Force

The company uses its own sales representatives to provide intensive training and service to eye care professionals. This direct approach helps doctors move away from older treatments toward newer, procedure-based solutions.

By the Numbers for 2026

  • Revenue grew 12.5% year-over-year to $19.7 million in the first quarter of 2026.
  • Net loss narrowed 8.3% to $13 million in the first quarter of 2026 compared to the same period in 2025.
  • Free cash flow improved 38.9% to negative $7.1 million in the first quarter of 2026.
  • Total cash and cash equivalents stood at $85 million as of March 31, 2026.
  • Gross margin for the first quarter of 2026 remained steady at 86.2%.

Evolution of Eye Care

Sight Sciences has transitioned from a development-stage firm to a commercial provider of specialized surgical and non-surgical eye tools. Its shift toward a leaner operating structure and focused clinical data supports its long-term goal of making its procedures the standard of care.

AI Generated • May 15, 2026

Industry

Healthcare Equipment and Supplies

Sector

Health Care

Employees

186

CEO

Paul Badawi, MBA

Website

www.sightsciences.com

Headquarters

Menlo Park, CA 94025, US

SGHT Financials

Key Financial Metrics (TTM)

Gross Margin

86.17%

Operating Margin

-44.82%

Net Income Margin

-46.83%

Return on Equity

-59.10%

Return on Capital

-35.43%

Return on Assets

-33.96%

Earnings Yield

-13.40%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$286.20MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

54.41M

Volume

95.73K

Avg. Volume

186.31K

Financials (TTM)

Gross Profit

$68.55M

Operating Income

-$35.65M

EBITDA

-$31.68M

Operating Cash Flow

-$25.12M

Capital Expenditure

-$284.00K

Free Cash Flow

-$25.40M

Cash & ST Invst.

$84.96M

Total Debt

$41.76M

Sight Sciences Performance Analysis

Sight Sciences annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 71,331,00045.7%
20232023-12-31USD 81,056,00013.6%
20242024-12-31USD 79,866,000-1.5%
20252025-12-31USD 77,363,000-3.1%
Sight Sciences sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3011.7%
Q32025-09-301.7%
Q42025-12-312.4%
Q12026-03-31-3.4%
Sight Sciences annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -1.8036.0%
20232023-12-31USD -1.14-36.6%
20242024-12-31USD -1.03-10.1%
20252025-12-31USD -0.74-28.3%
Sight Sciences sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3017.9%
Q32025-09-3030.4%
Q42025-12-3151.0%
Q12026-03-31-206.1%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$19.70M

+12.5%

Gross Profit

$16.98M

+12.5%

Gross Margin

86.19%

N/A

Market Cap

$286.20MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$1.54M

N/A

Employees

186

N/A

Net Income

-$12.98M

+8.3%

EBITDA

-$11.60M

+8.7%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$84.96M

-21.9%

Total Debt

$41.76M

+3.2%

Accounts Receivable

$10.60M

+12.4%

Inventory

$7.01M

+20.7%

Long Term Debt

$37.61M

-5.8%

Short Term Debt

$4.16M

+652.7%

Return on Assets

-33.96%

N/A

Return on Invested Capital

-38.95%

N/A

Free Cash Flow

-$7.09M

+38.9%

Operating Cash Flow

-$7.03M

+39.4%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
MASS908 Devices Inc.
$8.01+4.84%
SENSSenseonics Holdings, Inc.
$5.03-0.79%
OMIOwens & Minor, Inc.
$2.68+8.94%
PRQRProQR Therapeutics N.V.
$1.72-3.37%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDANvidia
$200.75+0.03%
AAPLApple
$308.91-0.07%
AMZNAmazon
$271.58+0.15%
INTCIntel
$90.20-0.01%

Questions About SGHT

What is the current price of Sight Sciences?

Sight Sciences is trading at $5.26 per share.

What is the 52-week range for Sight Sciences?

Over the past 52 weeks, Sight Sciences has traded between $3.11 and $9.24.

How much debt does Sight Sciences have?

As of the most recent reporting period, Sight Sciences reported total debt of $40.89M.

How much cash does Sight Sciences have on hand?

Sight Sciences reported $84.96M in cash and cash equivalents in its most recent financial results.

What is Sight Sciences’s dividend yield?

Sight Sciences does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services